CONMED
CNMD
Market cap $1.66B

53.55 USD

-1.42

2.58%

At close Jun 13, 4:00 PM EDT

After hours

53.55

+0.00

0.00%

1 day

-2.58%

5 days

-7.13%

1 month

-10.82%

3 months

-8.45%

6 months

-26.19%

Year to date

-20.49%

1 year

-26.48%

5 years

-26.97%

10 years

-4.80%

About: Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.

Employees: 3,900

Healthcare Medical Devices

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2,854% more call options, than puts

Call options by funds: $9.81M | Put options by funds: $332K

10% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 41

4% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 94

1% less funds holding

Funds holding: 278 [Q4 2024] → 276 (-2) [Q1 2025]

0.78% less ownership

Funds ownership: 115.86% [Q4 2024] → 115.08% (-0.78%) [Q1 2025]

12% less capital invested

Capital invested by funds: $2.45B [Q4 2024] → $2.15B (-$302M) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 0 (-2) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$55

3%

upside

Avg. target

$58

8%

upside

High target

$61

14%

upside

4 analyst ratings

0 positive

0%

4 neutral

100%

0 negative

0%

Needham Mike Matson	14%upside $61	Hold Downgraded	12 Jun 2025
JP Morgan Robbie Marcus	8%upside $58	Neutral Maintained	1 May 2025
Wells Fargo Vik Chopra	6%upside $57	Equal-Weight Maintained	1 May 2025
Stifel Rick Wise	3%upside $55	Hold Downgraded	28 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CNMD published over the past 30 days

Zacks Investment Research

Conmed (CNMD) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Conmed (CNMD) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. “LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board,” said Pat Beyer, P.

CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

CONMED Corporation Announces Quarterly Cash Dividend

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including ort.

CONMED Corporation Announces Quarterly Cash Dividend

Zacks Investment Research

Here's Why Conmed (CNMD) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Conmed (CNMD) is a Strong Value Stock

Zacks Investment Research

Why Conmed (CNMD) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Conmed (CNMD) is a Top Value Stock for the Long-Term

Zacks Investment Research

CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook

CNMD reports solid first-quarter results, driven by improving sales across both segments.

CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook

CONMED Corporation (CNMD) Q1 2025 Earnings Call Transcript

CONMED Corporation (NYSE:CNMD ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer and President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Matt O'Brien - Piper Sandler Robbie Marcus - JPMorgan Rick Wise - Stifel Young Li - Jefferies Travis Steed - Bank of America Mike Matson - Needham Operator Good day, and thank you for standing by. Welcome to CONMED's First Quarter Fiscal 2025 Earnings Conference Call.

CONMED Corporation (CNMD) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research

Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates

Conmed (CNMD) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.79 per share a year ago.

Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™